Drugs / Bioseal Fibrin Sealant
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT02094885 | Feb → Nov 2014 | vascular hemostatic disease | Ethicon, Inc. | Completed | No outcome recorded |
| Phase 4 | NCT02034799 | Nov 2013 → Aug 2014 | meningioma, vascular hemostatic disease | Ethicon, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bioseal Fibrin Sealant | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02094885 ↗ |
| Modality | Protein / enzyme biologic | “A porcine-derived fibrin sealant consisting of thrombin and fibrinogen” NCT02034799 ↗ |